GRAIL, Inc. — Investor Relations & Filings
Filings indexed
199
across all filing types
Latest filing
2026-06-01
Board/Management Inform…
Country
US
United States of America
Listing
US
GRAL
GRAIL, Inc. is a healthcare company dedicated to detecting cancer early. Its mission is to reduce the global burden of cancer through early diagnosis when treatment may be more effective. The company's flagship product is the Galleri® test, a blood-based multi-cancer early detection (MCED) test. The Galleri test is designed to screen for a signal shared by multiple types of cancer, including many that lack recommended screening methods, often before symptoms appear. GRAIL develops its technology by leveraging next-generation sequencing (NGS), machine learning, and data from population-scale clinical studies. The company's focus is on identifying deadly cancers in their initial stages to improve patient outcomes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-06-01 | English | |
| DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | |
| SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | |
| 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 47923163 | 8-K | 2026-06-01 | English | ||
| 38160818 | DEF 14A - GRAIL, Inc. (0001699031) (Filer) | 2026-04-28 | English | ||
| 33060498 | SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject) | 2026-03-27 | English | ||
| 32896830 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896829 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896831 | 4 - GRAIL, INC. (0001699031) (Filer) | 2026-03-04 | English | ||
| 32896832 | 8-K - GRAIL, INC. (0001699031) (Filer) | 2026-02-19 | English | ||
| 31355626 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 31355656 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31355567 | SCHEDULE 13G/A Filing | 2026-02-09 | English | ||
| 13013383 | FORM 4 | 2026-01-16 | English | ||
| 13013385 | FORM 4 | 2026-01-16 | English | ||
| 13013386 | FORM 4 | 2026-01-16 | English | ||
| 13013388 | 8-K | 2026-01-12 | English | ||
|
2025
1 filing
| |||||
| 13013387 | FORM 4 | 2025-12-05 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Vcanbio Cell & Gene Engineering Corp., Ltd
Focuses on stem cell bio-banking, genetic testing, and cell…
|
600645 | CN | Professional, scientific and te… |
|
VECTUS BIOSYSTEMS LIMITED
Develops therapeutics to reverse fibrosis and hypertension …
|
VBS | AU | Professional, scientific and te… |
|
Veradermics, Inc
Clinical-stage biopharmaceutical company developing medical…
|
MANE | US | Professional, scientific and te… |
|
Vera Therapeutics, Inc.
Clinical-stage biotech developing treatments for immunologi…
|
VERA | US | Professional, scientific and te… |
|
Veritas In Silico Inc.
A drug discovery company developing mRNA-targeting therapeu…
|
130A | JP | Professional, scientific and te… |
|
ViGenCell Inc.
Develops immune cell therapies to treat cancer and other in…
|
308080 | KR | Professional, scientific and te… |
|
Viking Therapeutics, Inc.
Clinical-stage biopharma developing therapies for metabolic…
|
VKTX | US | Professional, scientific and te… |
|
Vimta Labs Ltd.
Contract research and testing organization for life science…
|
VIMTALABS | IN | Professional, scientific and te… |
|
Vinext S.p.A.
Develops sustainable technology for the oenology and agri-f…
|
VNXT | IT | Professional, scientific and te… |
|
Virax Biolabs Group Ltd
Biotechnology company specializing in immune response detec…
|
VRAX | US | Professional, scientific and te… |
GRAIL, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31638/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31638 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31638 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31638 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31638}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for GRAIL, Inc. (id: 31638)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.